Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum

Progress in Neurobiology

Volumn 121, Issue , 2014, Pages 125-146

  Ríos, Juvenal A ^a   Cisternas, Pedro ^a   Arrese, Marco ^a,b   Barja, Salesa ^b   Inestrosa, Nibaldo C ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alzheimer's disease; Angiotensin II; Insulin; Leptin; Metabolic syndrome; Wnt

Indexed keywords

BETA CATENIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; TRIACYLGLYCEROL; WNT PROTEIN;

ADIPOGENESIS; ALZHEIMER DISEASE; AORTA COARCTATION; CHILDHOOD OBESITY; COGNITION; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOPROTEIN METABOLISM; MATERNAL OBESITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; REVIEW; WNT SIGNALING PATHWAY; ANIMAL; COMPLICATION; GENETICS; METABOLIC DISEASES; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; HUMANS; LEPTIN; METABOLIC DISEASES; WNT SIGNALING PATHWAY;

EID: 84908397502     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2014.07.004     Document Type: Review

References (408)

1. Accardi G., Caruso C., Colonna-Romano G., Camarda C., Monastero R., Candore G. Can Alzheimer disease be a form of type 3 diabetes?. Rejuvenation Res. 2012, 15:217-221.
2. Adeghate E., Donath T., Adem A. Alzheimer disease and diabetes mellitus: do they have anything in common?. Curr. Alzheimer Res. 2013, 10:609-617.
3. Agrawal R., Gomez-Pinilla F. 'Metabolic syndrome' in the brain: deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition. J. Physiol. 2012, 590:2485-2499.
4. Ahtiluoto S., Polvikoski T., Peltonen M., Solomon A., Tuomilehto J., Winblad B., Sulkava R., Kivipelto M. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010, 75:1195-1202.
5. Akinyemi R.O., Mukaetova-Ladinska E.B., Attems J., Ihara M., Kalaria R.N. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr. Alzheimer Res. 2013, 10:642-653.
6. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br. J. Clin. Pharmacol. 2010, 71:365-376.
7. Alagiakrishnan K., Sankaralingam S., Ghosh M., Mereu L., Senior P. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. Discov. Med. 2013, 16:277-286.
8. Alarcon M.A., Medina M.A., Hu Q., Avila M.E., Bustos B.I., Perez-Palma E., Peralta A., Salazar P., Ugarte G.D., Reyes A.E., Martin G.M., Opazo C., Moon R.T., De Ferrari G.V. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer's disease. Neurobiol. Aging 2013, 34:e1709-e1718.
9. Alosco M.L., Stanek K.M., Galioto R., Korgaonkar M.S., Grieve S.M., Brickman A.M., Spitznagel M.B., Gunstad J. Body mass index and brain structure in healthy children and adolescents. Int. J. Neurosci. 2013, 124(1):49-55. 10.3109/00207454.2013.817408.
10. Alvarez A.R., Godoy J.A., Mullendorff K., Olivares G.H., Bronfman M., Inestrosa N.C. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp. Cell Res. 2004, 297:186-196.
11. Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13:11-26.
12. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:645-655.
13. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:330-344.
14. Anstey K.J., Cherbuin N., Budge M., Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes. Rev. 2011, 12:e426-e437.
15. Ardiles A.O., Tapia-Rojas C.C., Mandal M., Alexandre F., Kirkwood A., Inestrosa N.C., Palacios A.G. Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13835-13840.
16. Arenas E. Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease. J. Mol. Cell Biol. 2014, 6:42-53.
17. Arnaiz P., Acevedo M., Barja S., Aglony M., Guzman B., Cassis B., Carvajal J., Moreno M., Navarrete C., Berrios X. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int. J. Cardiol. 2010, 138:138-144.
18. Arrazola M.S., Varela-Nallar L., Colombres M., Toledo E.M., Cruzat F., Pavez L., Assar R., Aravena A., Gonzalez M., Montecino M., Maass A., Martinez S., Inestrosa N.C. Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J. Cell. Physiol. 2009, 221:658-667.
19. Arregui A., Perry E.K., Rossor M., Tomlinson B.E. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J. Neurochem. 1982, 38:1490-1492.
20. Arrese M. Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat. Rev. Endocrinol. 2010, 6:660-661.
21. Ashrafian H., Harling L., Darzi A., Athanasiou T. Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?. Metab. Brain Dis. 2013, 28:341-353.
22. Asuni A.A., Hooper C., Reynolds C.H., Lovestone S., Anderton B.H., Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 2006, 24:3387-3392.
23. Atlas S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag. Care Pharm. 2007, 13:9-20.
24. Baker L.D., Cross D.J., Minoshima S., Belongia D., Watson G.S., Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011, 68:51-57.
25. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
26. Barger S.W., DeWall K.M., Liu L., Mrak R.E., Griffin W.S. Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. J. Neuropathol. Exp. Neurol. 2008, 67:773-783.
27. Barja S., Acevedo M., Arnaiz P., Berrios X., Bambs C., Guzman B., Carvajal J., Cassis B., Navarrete C. Early markers for atherosclerosis and metabolic syndrome in children. Rev. Med. Chile 2009, 137:522-530.
28. Barja S., Arteaga A., Acosta A.M., Hodgson M.I. Insulin resistance and other expressions of metabolic syndrome in obese Chilean children. Rev. Med. Chile 2003, 131:259-268.
29. Barja S., Hodgson M.I., Acosta A.M., Arteaga A. Glucose intolerance in obese children: a preliminary study. Rev. Med. Chile 2003, 131:419-426.
30. Barone E., Di Domenico F., Butterfield D.A. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem. Pharmacol. 2013, 88(4):605-616. 10.1016/j.bcp.2013.10.030.
31. Barone E., Di Domenico F., Mancuso C., Butterfield D.A. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol. Dis. 2014, 62:144-159.
32. Barrow J.R. Wnt/PCP signaling: a veritable polar star in establishing patterns of polarity in embryonic tissues. Semin. Cell Dev. Biol. 2006, 17:185-193.
33. Bassil F., Fernagut P.O., Bezard E., Meissner W.G. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. Prog. Neurobiol. 2014, 118C:1-18.
34. Baumann M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J. Am. Soc. Hypertens. 2012, 6:427-435.
35. Behari J. The Wnt/beta-catenin signaling pathway in liver biology and disease. Expert Rev. Gastroenterol. Hepatol. 2010, 4:745-756.
36. Behari J., Yeh T.H., Krauland L., Otruba W., Cieply B., Hauth B., Apte U., Wu T., Evans R., Monga S.P. Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am. J. Pathol. 2010, 176:744-753.
37. Belsky D.W., Caspi A., Goldman-Mellor S., Meier M.H., Ramrakha S., Poulton R., Moffitt T.E. Is obesity associated with a decline in intelligence quotient during the first half of the life course?. Am. J. Epidemiol. 2013, 178:1461-1468.
38. Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
39. Benzler J., Andrews Z.B., Pracht C., Stohr S., Shepherd P.R., Grattan D.R., Tups A. Hypothalamic WNT signalling is impaired during obesity and reinstated by leptin treatment in male mice. Endocrinology 2013, 154:4737-4745.
40. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
41. Berwick D.C., Harvey K. The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1123-1128.
42. Bettens K., Sleegers K., Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013, 12:92-104.
43. Bhat N.R. Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J. Neurochem. 2010, 115:551-562.
44. Bitel C.L., Kasinathan C., Kaswala R.H., Klein W.L., Frederikse P.H. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J. Alzheimers Dis. 2012, 32:291-305.
45. Blankesteijn W.M., van de Schans V.A., ter Horst P., Smits J.F. The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol. Sci. 2008, 29:175-180.
46. Boitard C., Etchamendy N., Sauvant J., Aubert A., Tronel S., Marighetto A., Laye S., Ferreira G. Juvenile, but not adult exposure to high-fat diet impairs relational memory and hippocampal neurogenesis in mice. Hippocampus 2012, 22:2095-2100.
47. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Investig. 2012, 122:1339-1353.
48. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000, 19:141-148.
49. Bosco D., Fava A., Plastino M., Montalcini T., Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 2011, 15:1807-1821.
50. Boudreau D.M., Malone D.C., Raebel M.A., Fishman P.A., Nichols G.A., Feldstein A.C., Boscoe A.N., Ben-Joseph R.H., Magid D.J., Okamoto L.J. Health care utilization and costs by metabolic syndrome risk factors. Metab. Syndr. Relat. Disord. 2009, 7:305-314.
51. Bovolenta P., Esteve P., Ruiz J.M., Cisneros E., Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 2008, 121:737-746.
52. Brack A.S., Conboy I.M., Conboy M.J., Shen J., Rando T.A. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008, 2:50-59.
53. Braidy N., Munoz P., Palacios A.G., Castellano-Gonzalez G., Inestrosa N.C., Chung R.S., Sachdev P., Guillemin G.J. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J. Neural Transm. 2012, 119:173-195.
54. Brown C., Donnelly T.M. Cataracts and reduced fertility in degus (Octodon degus). Contracts secondary to spontaneous diabetes mellitus. Lab Animal 2001, 30:25-26.
55. Bruce A.S., Lepping R.J., Bruce J.M., Cherry J.B., Martin L.E., Davis A.M., Brooks W.M., Savage C.R. Brain responses to food logos in obese and healthy weight children. J. Pediatr. 2013, 162:759-764. e752.
56. Bruehl H., Sweat V., Tirsi A., Shah B., Convit A. Obese adolescents with type 2 diabetes mellitus have hippocampal and frontal lobe volume reductions. Neurosci. Med. 2011, 2:34-42.
57. Bucht G., Sandman P.O. Nutritional aspects of dementia, especially Alzheimer's disease. Age Ageing 1990, 19:S32-S36.
58. Budnik V., Salinas P.C. Wnt signaling during synaptic development and plasticity. Curr. Opin. Neurobiol. 2011, 21:151-159.
59. Burns C.M., Chen K., Kaszniak A.W., Lee W., Alexander G.E., Bandy D., Fleisher A.S., Caselli R.J., Reiman E.M. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 2013, 80:1557-1564.
60. Bush A.I., Masters C.L., Tanzi R.E. Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11193-11194.
61. Businaro R., Ippoliti F., Ricci S., Canitano N., Fuso A. Alzheimer's disease promotion by obesity: induced mechanisms-molecular links and perspectives. Curr. Gerontol. Geriatr. Res. 2012, 2012:986823.
62. Cadigan K.M., Waterman M.L. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb. Perspect. Biol. 2012, 4(11). pii:a007906. 10.1101/cshperspect.a007906.
63. Cai Z., Zhao B., Ratka A. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neuromol. Med. 2011, 13:223-250.
64. Calvo-Ochoa E., Arias C. Cellular and metabolic alterations in the hippocampus caused by insulin signaling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease. Animal models of study. Diabet./Metab. Res. Rev. 2014, 10.1002/dmrr.2531.
65. Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A.J., Caruso A., Storto M., Gaviraghi G., Terstappen G.C., Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci.: Off. J. Soc. Neurosci. 2004, 24:6021-6027.
66. Caricasole A., Ferraro T., Iacovelli L., Barletta E., Caruso A., Melchiorri D., Terstappen G.C., Nicoletti F. Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J. Biol. Chem. 2003, 278:37024-37031.
67. Cariou B., Charbonnel B., Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol. Metab. 2012, 23:205-215.
68. Carnevale D., Lembo G. 'Alzheimer-like' pathology in a murine model of arterial hypertension. Biochem. Soc. Trans. 2011, 39:939-944.
69. Carstensen M., Herder C., Kempf K., Erlund I., Martin S., Koenig W., Sundvall J., Bidel S., Kuha S., Roden M., Tuomilehto J. Sfrp5 correlates with insulin resistance and oxidative stress. Eur. J. Clin. Invest. 2013, 43:350-357.
70. Caruso A., Motolese M., Iacovelli L., Caraci F., Copani A., Nicoletti F., Terstappen G.C., Gaviraghi G., Caricasole A. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J. Neurochem. 2006, 98:364-371.
71. Caselli R.J., Dueck A.C., Locke D.E., Sabbagh M.N., Ahern G.L., Rapcsak S.Z., Baxter L.C., Yaari R., Woodruff B.K., Hoffman-Snyder C., Rademakers R., Findley S., Reiman E.M. Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 2011, 76:1078-1084.
72. Cassani E., Cereda E., Barichella M., Madio C., Cancello R., Caccialanza R., Zini M., Cilia R., Pezzoli G. Cardiometabolic factors and disease duration in patients with Parkinson's disease. Nutrition 2013, 29:1331-1335.
73. Castellani R.J., Rolston R.K., Smith M.A. Alzheimer disease. Dis. Mon. 2010, 56:484-546.
74. Castoldi G., Redaelli S., van de Greef W.M., di Gioia C.R., Busca G., Sperti G., Stella A. Angiotensin II modulates frizzled-2 receptor expression in rat vascular smooth muscle cells. Clin. Sci. (Lond.) 2005, 108:523-530.
75. Cereda E., Cassani E., Barichella M., Caccialanza R., Pezzoli G. Anthropometric indices of fat distribution and cardiometabolic risk in Parkinson's disease. Nutr. Metab. Cardiovasc. Dis. 2013, 23:264-271.
76. Ceriello A., Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic Med. 2008, 25:1151-1156.
77. Cerpa W., Dinamarca M.C., Inestrosa N.C. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr. Alzheimer Res. 2008, 5:233-243.
78. Cerpa W., Varela-Nallar L., Reyes A.E., Minniti A.N., Inestrosa N.C. Is there a role for copper in neurodegenerative diseases?. Mol. Aspects Med. 2005, 26:405-420.
79. Cisternas P., Henriquez J.P., Brandan E., Inestrosa N.C. Wnt signaling in skeletal muscle dynamics: myogenesis. Neuromuscul. Synap. Fibros. Mol. Neurobiol. 2013, 49(1):574-589. 10.1007/s12035-013-8540-5.
80. Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013, 14:311-321.
81. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
82. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
83. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
84. Colombres M., Henriquez J.P., Reig G.F., Scheu J., Calderon R., Alvarez A., Brandan E., Inestrosa N.C. Heparin activates Wnt signaling for neuronal morphogenesis. J. Cell. Physiol. 2008, 216:805-815.
85. Convit A. Obesity is associated with structural and functional brain abnormalities: where do we go from here?. Psychosom. Med. 2012, 74:673-674.
86. Cook S., Weitzman M., Auinger P., Nguyen M., Dietz W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 2003, 157:821-827.
87. Coppari R., Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discov. 2012, 11:692-708.
88. Corripio R., Gonzalez-Clemente J.M., Jacobo P.S., Silvia N., Lluis G., Joan V., Assumpta C. Plasma brain-derived neurotrophic factor in prepubertal obese children: results from a 2-year lifestyle intervention programme. Clin. Endocrinol. (Oxf.) 2012, 77:715-720.
89. Craft S., Cholerton B., Baker L.D. Insulin and Alzheimer's disease: untangling the web. J. Alzheimers Dis. 2013, 33(Suppl. 1):S263-S275.
90. Craft S., Dagogo-Jack S.E., Wiethop B.V., Murphy C., Nevins R.T., Fleischman S., Rice V., Newcomer J.W., Cryer P.E. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav. Neurosci. 1993, 107:926-940.
91. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
92. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
93. Csiszar A., Tucsek Z., Toth P., Sosnowska D., Gautam T., Koller A., Deak F., Sonntag W.E., Ungvari Z. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H1120-H1130.
94. Cunnane S., Nugent S., Roy M., Courchesne-Loyer A., Croteau E., Tremblay S., Castellano A., Pifferi F., Bocti C., Paquet N., Begdouri H., Bentourkia M., Turcotte E., Allard M., Barberger-Gateau P., Fulop T., Rapoport S.I. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011, 27:3-20.
95. Currais A., Prior M., Lo D., Jolivalt C., Schubert D., Maher P. Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice. Aging Cell 2012, 11:1017-1026.
96. Chandak G.R., Janipalli C.S., Bhaskar S., Kulkarni S.R., Mohankrishna P., Hattersley A.T., Frayling T.M., Yajnik C.S. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 2007, 50:63-67.
97. Chen J., Guan Z., Wang L., Song G., Ma B., Wang Y. Meta-analysis: overweight, obesity, and Parkinson's disease. Int. J. Endocrinol. 2014, 2010:203930.
98. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108:21-43.
99. Chiang Y.T., Ip W., Jin T. The role of the Wnt signaling pathway in incretin hormone production and function. Front. Physiol. 2012, 3:273.
100. Cho Y.M., Kim T.H., Lim S., Choi S.H., Shin H.D., Lee H.K., Park K.S., Jang H.C. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia 2009, 52:253-261.
101. Dalamaga M., Chou S.H., Shields K., Papageorgiou P., Polyzos S.A., Mantzoros C.S. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013.
102. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454.
103. Daskalopoulos E.P., Hermans K.C., Janssen B.J., Matthijs Blankesteijn W. Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox?. Trends Cardiovasc. Med. 2013, 23:121-127.
104. Datar A., Sturm R. Childhood overweight and elementary school outcomes. Int. J. Obes. 2006, 30:1449-1460.
105. Datiles M.B., Fukui H. Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil. Curr. Eye Res. 1989, 8:233-237.
106. de Boo H.A., Harding J.E. The developmental origins of adult disease (Barker) hypothesis. Aust. N. Z. J. Obst. Gynaecol. 2006, 46:4-14.
107. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 2013, 123:531-539.
108. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
109. De Felice F.G., Lourenco M.V., Ferreira S.T. How does brain insulin resistance develop in Alzheimer's disease?. Alzheimer's Dement.: J Alzheimer's Assoc. 2014, 10:S26-S32.
110. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
111. De Ferrari G., Avila M., Medina M., Perez-Palma E., Bustos B., Alarcon M. Wnt/beta-catenin signaling in Alzheimer's disease. CNS Neurol. Disord. Drug Targ. 2013.
112. De Ferrari G.V., Chacon M.A., Barria M.I., Garrido J.L., Godoy J.A., Olivares G., Reyes A.E., Alvarez A., Bronfman M., Inestrosa N.C. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 2003, 8:195-208.
113. De Ferrari G.V., Inestrosa N.C. Wnt signaling function in Alzheimer's disease. Brain Res. Brain Res. Rev. 2000, 33:1-12.
114. De Ferrari G.V., Papassotiropoulos A., Biechele T., Wavrant De-Vrieze F., Avila M.E., Major M.B., Myers A., Saez K., Henriquez J.P., Zhao A., Wollmer M.A., Nitsch R.M., Hock C., Morris C.M., Hardy J., Moon R.T. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9434-9439.
115. de la Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:35-66.
116. de la Monte S.M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012, 72:49-66.
117. de la Monte S.M., Neusner A., Chu J., Lawton M. Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis. J. Alzheimer's Dis. 2009, 17:519-529.
118. de la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 2013, 88(4):548-559. 10.1016/j.bcp.2013.12.012.
119. de la Monte S.M., Wands J.R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2008, 2:1101-1113.
120. Descamps B., Sewduth R., Ferreira Tojais N., Jaspard B., Reynaud A., Sohet F., Lacolley P., Allieres C., Lamaziere J.M., Moreau C., Dufourcq P., Couffinhal T., Duplaa C. Frizzled 4 regulates arterial network organization through noncanonical Wnt/planar cell polarity signaling. Circ. Res. 2012, 110:47-58.
121. Di Paolo G., Kim T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 2011, 12:284-296.
122. Dou J.T., Chen M., Dufour F., Alkon D.L., Zhao W.Q. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn. Mem. 2005, 12:646-655.
123. Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011, 51:1014-1026.
124. Duron E., Hanon O. Hypertension, cognitive decline and dementia. Arch. Cardiovasc. Dis. 2008, 101:181-189.
125. Duron E., Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc. Health Risk Manag. 2008, 4:363-381.
126. Ehrlund A., Mejhert N., Lorente-Cebrian S., Astrom G., Dahlman I., Laurencikiene J., Ryden M. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J. Clin. Endocrinol. Metab. 2013, 98:E503-E508.
127. Farley D.M., Choi J., Dudley D.J., Li C., Jenkins S.L., Myatt L., Nathanielsz P.W. Placental amino acid transport and placental leptin resistance in pregnancies complicated by maternal obesity. Placenta 2010, 31:718-724.
128. Farooqui A.A., Farooqui T., Panza F., Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell. Mol. Life Sci. 2012, 69:741-762.
129. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5856-5861.
130. Ferreira S.T., Clarke J.R., Bomfim T.R., De Felice F.G. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's Dement.: J. Alzheimer's Assoc. 2014, 10:S76-S83.
131. Fewlass D.C., Noboa K., Pi-Sunyer F.X., Johnston J.M., Yan S.D., Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004, 18:1870-1878.
132. Fontaine K.R., Redden D.T., Wang C., Westfall A.O., Allison D.B. Years of life lost due to obesity. J. Am. Med. Assoc. 2003, 289:187-193.
133. Franke K., Gaser C., Manor B., Novak V. Advanced BrainAGE in older adults with type 2 diabetes mellitus. Front. Aging Neurosci. 2013, 5:90.
134. Freiherr J., Hallschmid M., Frey W.H., Brunner Y.F., Chapman C.D., Holscher C., Craft S., De Felice F.G., Benedict C. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 7:505-514. 10.1007/s40263-013-0076-8.
135. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 2007, 282:37006-37015.
136. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008, 264:224-236.
137. Gabuzda D., Busciglio J., Chen L.B., Matsudaira P., Yankner B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269:13623-13628.
138. Gao C., Holscher C., Liu Y., Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 2012, 23:1-11.
139. Gardener S., Gu Y., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., Taddei K., Mondal A., Ward V.K., Scarmeas N., Barnes M., Ellis K.A., Head R., Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Szoeke C., Martins R.N., Group A.R. Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population. Transl. Psychiatry 2012, 2:e164.
140. Garza J.C., Guo M., Zhang W., Lu X.Y. Leptin increases adult hippocampal neurogenesis in vivo and in vitro. J. Biol. Chem. 2008, 283:18238-18247.
141. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
142. Gasparini L., Netzer W.J., Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol. Sci. 2002, 23:288-293.
143. Gauger K.J., Bassa L.M., Henchey E.M., Wyman J., Bentley B., Brown M., Shimono A., Schneider S.S. Mice deficient in sfrp1 exhibit increased adiposity, dysregulated glucose metabolism, and enhanced macrophage infiltration. PLOS ONE 2013, 8:e78320.
144. Gelman L., Feige J.N., Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim. Biophys. Acta 2007, 1771:1094-1107.
145. Gentile M.T., Poulet R., Di Pardo A., Cifelli G., Maffei A., Vecchione C., Passarelli F., Landolfi A., Carullo P., Lembo G. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol. Aging 2009, 30:222-228.
146. Ginter E., Simko V. Global prevalence and future of diabetes mellitus. Adv. Exp. Med. Biol. 2012, 771:35-41.
147. Ginter E., Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv. Exp. Med. Biol. 2012, 771:42-50.
148. Godoy J., Rios J., Zolezzi J., Braidy N., Inestrosa N. Signaling pathway cross talk in Alzheimer's disease. Cell Commun. Signal. 2014, 12:23.
149. Godoy J.A., Zolezzi J.M., Braidy N., Inestrosa N.C. Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol. Neurobiol. 2014, 10.1007/s12035-014-8645-5.
150. Goedeke L., Fernandez-Hernando C. Regulation of cholesterol homeostasis. Cell. Mol. Life Sci. 2012, 69:915-930.
151. Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat. Rev. Neurosci. 2008, 9:568-578.
152. Gonzalez A.A., Luffman C., Bourgeois C.R., Vio C.P., Prieto M.C. Angiotensin II-independent upregulation of cyclooxygenase-2 by activation of the (Pro)renin receptor in rat renal inner medullary cells. Hypertension 2013, 61:443-449.
153. Grant S.F., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., Helgason A., Stefansson H., Emilsson V., Helgadottir A., Styrkarsdottir U., Magnusson K.P., Walters G.B., Palsdottir E., Jonsdottir T., Gudmundsdottir T., Gylfason A., Saemundsdottir J., Wilensky R.L., Reilly M.P., Rader D.J., Bagger Y., Christiansen C., Gudnason V., Sigurdsson G., Thorsteinsdottir U., Gulcher J.R., Kong A., Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006, 38:320-323.
154. Groves C.J., Zeggini E., Minton J., Frayling T.M., Weedon M.N., Rayner N.W., Hitman G.A., Walker M., Wiltshire S., Hattersley A.T., McCarthy M.I. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006, 55:2640-2644.
155. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
156. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Curr. Opin. Cardiol. 2006, 21:1-6.
157. Gustafson B., Smith U. The WNT inhibitor Dickkopf 1 and bone morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in humans. Diabetes 2012, 61:1217-1224.
158. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J. Neurol. Neurosurg. Psychiatry 2009, 80:13-17.
159. Haase N., Herse F., Spallek B., Haase H., Morano I., Qadri F., Szijarto I.A., Rohm I., Yilmaz A., Warrington J.P., Ryan M.J., Gollasch M., Muller D.N., Dechend R., Wallukat G. Amyloid-beta peptides activate alpha1-adrenergic cardiovascular receptors. Hypertension 2013, 62:966-972.
160. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 2006, 97:3A-11A.
161. Haj-ali V., Mohaddes G., Babri S.H. Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav. Neurosci. 2009, 123:1309-1314.
162. Hampel H., Prvulovic D., Teipel S., Jessen F., Luckhaus C., Frolich L., Riepe M.W., Dodel R., Leyhe T., Bertram L., Hoffmann W., Faltraco F., German Task Force on Alzheimer's Disease The future of Alzheimer's disease: the next 10 years. Prog. Neurobiol. 2011, 95:718-728.
163. Han S.H., Einstein G., Weisgraber K.H., Strittmatter W.J., Saunders A.M., Pericak-Vance M., Roses A.D., Schmechel D.E. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J. Neuropathol. Exp. Neurol. 1994, 53:535-544.
164. Han S.H., Hulette C., Saunders A.M., Einstein G., Pericak-Vance M., Strittmatter W.J., Roses A.D., Schmechel D.E. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp. Neurol. 1994, 128:13-26.
165. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997, 20:154-159.
166. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., Heun R., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
167. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272:827-829.
168. He W., Dai C., Li Y., Zeng G., Monga S.P., Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 2009, 20:765-776.
169. He W., Kang Y.S., Dai C., Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol. 2011, 22:90-103.
170. Heneka M.T., Reyes-Irisarri E., Hull M., Kummer M.P. Impact and therapeutic potential of PPARs in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9:643-650.
171. Hirabayashi S., Baranski T.J., Cagan R.L. Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. Cell 2013, 154:664-675.
172. Ho R.C., Niti M., Yap K.B., Kua E.H., Ng T.P. Metabolic syndrome and cognitive decline in Chinese older adults: results from the Singapore longitudinal ageing studies. Am. J. Geriatr. Psychiatry 2008, 16:519-522.
173. Hodar C., Assar R., Colombres M., Aravena A., Pavez L., Gonzalez M., Martinez S., Inestrosa N.C., Maass A. Genome-wide identification of new Wnt/beta-catenin target genes in the human genome using CART method. BMC Genom. 2010, 11:348.
174. Holscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimer's Dement.: J. Alzheimer's Assoc. 2014, 10:S33-S37.
175. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006312.
176. Homan R., Hanselman J.C., Bak-Mueller S., Washburn M., Lester P., Jensen H.E., Pinkosky S.L., Castle C., Taylor B. Atherosclerosis in Octodon degus (degu) as a model for human disease. Atherosclerosis 2010, 212:48-54.
177. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104:1433-1439.
178. Hoppener J.W., Ahren B., Lips C.J. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 2000, 343:411-419.
179. Hoppener J.W., Lips C.J. Role of islet amyloid in type 2 diabetes mellitus. Int. J. Biochem. Cell Biol. 2006, 38:726-736.
180. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv. Exp. Med. Biol. 2004, 541:135-152.
181. Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 2001, 276:47863-47868.
182. Huang C.C., Chung C.M., Leu H.B., Lin L.Y., Chiu C.C., Hsu C.Y., Chiang C.H., Huang P.H., Chen T.J., Lin S.J., Chen J.W., Chan W.L. Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLOS ONE 2014, 9:e87095.
183. Huang P.L. A comprehensive definition for metabolic syndrome. Dis. Model Mech. 2009, 2:231-237.
184. Huffman D.M., Barzilai N. Role of visceral adipose tissue in aging. Biochim. Biophys. Acta 2009, 1790:1117-1123.
185. Humphries S.E., Gable D., Cooper J.A., Ireland H., Stephens J.W., Hurel S.J., Li K.W., Palmen J., Miller M.A., Cappuccio F.P., Elkeles R., Godsland I., Miller G.J., Talmud P.J. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J. Mol. Med. (Berl.) 2006, 84:1005-1014.
186. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 2008, 9:125-138.
187. Inestrosa N.C., Arenas E. Emerging roles of Wnts in the adult nervous system. Nat. Rev. Neurosci. 2010, 11:77-86.
188. Inestrosa N.C., Carvajal F.J., Zolezzi J.M., Tapia-Rojas C., Serrano F., Karmelic D., Toledo E.M., Toro A., Toro J., Santos M.J. Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. J. Alzheimer's Dis. 2013, 33:941-959.
189. Inestrosa N.C., Godoy J.A., Quintanilla R.A., Koenig C.S., Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 2005, 304:91-104.
190. Inestrosa N.C., Montecinos-Oliva C., Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. J. Neuroimmune Pharmacol. 2012, 7:788-807.
191. Inestrosa N.C., Reyes A.E., Chacon M.A., Cerpa W., Villalon A., Montiel J., Merabachvili G., Aldunate R., Bozinovic F., Aboitiz F. Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol. Aging 2005, 26:1023-1028.
192. Inestrosa N.C., Toledo E.M. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Mol. Neurodegener. 2008, 3:9.
193. Inestrosa N.C., Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer's disease. J. Mol. Cell Biol. 2014, 6:64-74.
194. Ingalls A.M., Dickie M.M., Snell G.D. Obese, a new mutation in the house mouse. J. Hered. 1950, 41:317-318.
195. Ip W., Chiang Y.T., Jin T. The involvement of the Wnt signaling pathway and TCF7L2 in diabetes mellitus: the current understanding, dispute, and perspective. Cell Biosci. 2012, 2:28.
196. Isakson P., Hammarstedt A., Gustafson B., Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 2009, 58:1550-1557.
197. Jackson K., Barisone G.A., Diaz E., Jin L.W., DeCarli C., Despa F. Amylin deposition in the brain: a second amyloid in Alzheimer disease?. Ann. Neurol. 2013, 74:517-526.
198. Jauch-Chara K., Oltmanns K.M. Obesity - a neuropsychological disease? Systematic review and neuropsychological model. Prog. Neurobiol. 2014, 114:84-101.
199. Kakinuma Y., Hama H., Sugiyama F., Goto K., Murakami K., Fukamizu A. Anti-apoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knock-out mice. Neurosci. Lett. 1997, 232:167-170.
200. Kalaria R.N., Akinyemi R., Ihara M. Does vascular pathology contribute to Alzheimer changes?. J. Neurol. Sci. 2012, 322:141-147.
201. Kamphuis P.J., Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease?. J. Alzheimers Dis. 2010, 20:765-775.
202. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., Koo E.H. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Investig. 2000, 106:1159-1166.
203. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011, 10:187-198.
204. Kennell J.A., MacDougald O.A. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J. Biol. Chem. 2005, 280:24004-24010.
205. Killick R., Ribe E.M., Al-Shawi R., Malik B., Hooper C., Fernandes C., Dobson R., Nolan P.M., Lourdusamy A., Furney S., Lin K., Breen G., Wroe R., To A.W., Leroy K., Causevic M., Usardi A., Robinson M., Noble W., Williamson R., Lunnon K., Kellie S., Reynolds C.H., Bazenet C., Hodges A., Brion J.P., Stephenson J., Simons J.P., Lovestone S. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the Wnt-PCP-JNK pathway. Mol. Psychiatry 2014, 19:88-98.
206. Kim K., Lu Z., Hay E.D. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 2002, 26:463-476.
207. Kim M.H., Hong S.H., Lee M.K. Insulin receptor-overexpressing beta-cells ameliorate hyperglycemia in diabetic rats through Wnt signaling activation. PLOS ONE 2013, 8:e67802.
208. Kim M.H., Jee J.H., Park S., Lee M.S., Kim K.W., Lee M.K. Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J. Endocrinol. 2014, 220:117-128.
209. Kim M.H., Kang K.S. Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling. Prev. Med. 2012, 54(Suppl.):S57-S63.
210. Kivipelto M., Laakso M.P., Tuomilehto J., Nissinen A., Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs 2002, 16:435-444.
211. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005, 62:1556-1560.
212. Kravitz E., Schmeidler J., Schnaider Beeri M. Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. Endocrinol. Metab. Clin. North Am. 2013, 42:489-501.
213. L'Episcopo F., Tirolo C., Caniglia S., Testa N., Morale M.C., Serapide M.F., Pluchino S., Marchetti B. Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J. Mol. Cell Biol. 2014, 6:13-26.
214. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
215. Lagathu C., Christodoulides C., Tan C.Y., Virtue S., Laudes M., Campbell M., Ishikawa K., Ortega F., Tinahones F.J., Fernandez-Real J.M., Oresic M., Sethi J.K., Vidal-Puig A. Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity. Int. J. Obes. (Lond.) 2010, 34:1695-1705.
216. Lahoz C., Schaefer E.J., Cupples L.A., Wilson P.W., Levy D., Osgood D., Parpos S., Pedro-Botet J., Daly J.A., Ordovas J.M. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154:529-537.
217. Lande M.B., Kaczorowski J.M., Auinger P., Schwartz G.J., Weitzman M. Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States. J. Pediatrics 2003, 143:720-724.
218. Leroy K., Yilmaz Z., Brion J.P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol. 2007, 33:43-55.
219. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
220. Li C., Zhao R., Gao K., Wei Z., Yin M.Y., Lau L.T., Chui D., Hoi Yu A.C. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:67-80.
221. Li J., Deng J., Sheng W., Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol. Biochem. Behav. 2012, 101:564-574.
222. Li X., Kumar Y., Zempel H., Mandelkow E.M., Biernat J., Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 2011, 30:4825-4837.
223. Lieb W., Beiser A.S., Vasan R.S., Tan Z.S., Au R., Harris T.B., Roubenoff R., Auerbach S., DeCarli C., Wolf P.A., Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. J. Am. Med. Assoc. 2009, 302:2565-2572.
224. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
225. Liu W., Singh R., Choi C.S., Lee H.Y., Keramati A.R., Samuel V.T., Lifton R.P., Shulman G.I., Mani A. Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure. J. Biol. Chem. 2012, 287:7213-7223.
226. Lokken K.L., Boeka A.G., Austin H.M., Gunstad J., Harmon C.M. Evidence of executive dysfunction in extremely obese adolescents: a pilot study. Surg. Obes. Relat. Dis.: Off. J. Am. Soc. Bariatr. Surg. 2009, 5:547-552.
227. Long-Smith C.M., Manning S., McClean P.L., Coakley M.F., O'Halloran D.J., Holscher C., O'Neill C. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromol. Med. 2013, 15:102-114.
228. Longo K.A., Wright W.S., Kang S., Gerin I., Chiang S.H., Lucas P.C., Opp M.R., MacDougald O.A. Wnt10b inhibits development of white and brown adipose tissues. J. Biol. Chem. 2004, 279:35503-35509.
229. Lovestone S. It takes tau to tangle - the molecular biology of Alzheimer's disease. Trans. Med. Soc. Lond. 2001, 118:54-56.
230. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B., Stabel S., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 1994, 4:1077-1086.
231. Luzzo K.M., Wang Q., Purcell S.H., Chi M., Jimenez P.T., Grindler N., Schedl T., Moley K.H. High fat diet induced developmental defects in the mouse: oocyte meiotic aneuploidy and fetal growth retardation/brain defects. PLoS ONE 2012, 7:e49217.
232. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., Zhang M., Yang Y., Cai F., Woodgett J., Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Investig. 2013, 123:224-235.
233. Maayan L., Hoogendoorn C., Sweat V., Convit A. Disinhibited eating in obese adolescents is associated with orbitofrontal volume reductions and executive dysfunction. Obesity 2011, 19:1382-1387.
234. Mahdi T., Hanzelmann S., Salehi A., Muhammed S.J., Reinbothe T.M., Tang Y., Axelsson A.S., Zhou Y., Jing X., Almgren P., Krus U., Taneera J., Blom A.M., Lyssenko V., Esguerra J.L., Hansson O., Eliasson L., Derry J., Zhang E., Wollheim C.B., Groop L., Renstrom E., Rosengren A.H. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab. 2012, 16:625-633.
235. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
236. Malek-Ahmadi M., Beach T., Obradov A., Obradov A., Sue L., Belden C., Davis K., Walker D.G., Lue L., Adem A., Sabbagh M.N. Type 2 diabetes is associated with increased Alzheimer's disease neuropathology in ApoE epsilon4 carriers. Curr. Alzheimer Res. 2013, 6:654-659.
237. Marchetti B., Pluchino S. Wnt your brain be inflamed? Yes, it Wnt!. Trends Mol. Med. 2013, 19:144-156.
238. Mardones F., Arnaiz P., Barja S., Giadach C., Villarroel L., Dominguez A., Castillo O., Farias M. Nutritional status, metabolic syndrome and insulin resistance in children from Santiago, Chile. Nutr. Hosp. 2013, 28:1999-2005.
239. Mattson M.P., Rydel R.E., Lieberburg I., Smith-Swintosky V.L. Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Ann. N. Y. Acad. Sci. 1993, 679:1-21.
240. Mayeux R., Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect Med. 2012, 2:1-18.
241. Mayeux R., Stern Y., Ottman R., Tatemichi T.K., Tang M.X., Maestre G., Ngai C., Tycko B., Ginsberg H. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann. Neurol. 1993, 34:752-754.
242. McDonald R.B., Ramsey J.J. Honoring Clive McCay and 75 years of calorie restriction research. J. Nutr. 2010, 140:1205-1210.
243. Medhi B., Chakrabarty M. Insulin resistance: an emerging link in Alzheimer's disease. Neurol. Sci. 2013, 34(10):1719-1725. 10.1007/s10072-013-1454-1.
244. Mehla J., Chauhan B.C., Chauhan N.B. Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J. Alzheimer's Dis. 2014, 39:145-162.
245. Melka M.G., Gillis J., Bernard M., Abrahamowicz M., Chakravarty M.M., Leonard G.T., Perron M., Richer L., Veillette S., Banaschewski T., Barker G.J., Buchel C., Conrod P., Flor H., Heinz A., Garavan H., Bruhl R., Mann K., Artiges E., Lourdusamy A., Lathrop M., Loth E., Schwartz Y., Frouin V., Rietschel M., Smolka M.N., Strohle A., Gallinat J., Struve M., Lattka E., Waldenberger M., Schumann G., Pavlidis P., Gaudet D., Paus T., Pausova Z. FTO, obesity and the adolescent brain. Hum. Mol. Genet. 2013, 22:1050-1058.
246. Merched A., Xia Y., Visvikis S., Serot J.M., Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 2000, 21:27-30.
247. Messier C., Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast. 2005, 12:311-328.
248. Min L.J., Mogi M., Iwai M., Horiuchi M. Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res. Rev. 2009, 8:113-121.
249. Miranda S., Opazo C., Larrondo L.F., Munoz F.J., Ruiz F., Leighton F., Inestrosa N.C. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 2000, 62:633-648.
250. Misiak B., Leszek J., Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease - the emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 2012, 89:144-149.
251. Mitchell A.C., Leak R.K., Zigmond M.J., Cameron J.L., Mirnics K. Gene transcripts associated with BMI in the motor cortex and caudate nucleus of calorie restricted rhesus monkeys. Genomics 2012, 99:144-151.
252. Miyake K., Horikawa Y., Hara K., Yasuda K., Osawa H., Furuta H., Hirota Y., Yamagata K., Hinokio Y., Oka Y., Iwasaki N., Iwamoto Y., Yamada Y., Seino Y., Maegawa H., Kashiwagi A., Yamamoto K., Tokunaga K., Takeda J., Makino H., Nanjo K., Kadowaki T., Kasuga M. Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. J. Hum. Genet. 2008, 53:174-180.
253. Moreno-Lopez L., Soriano-Mas C., Delgado-Rico E., Rio-Valle J.S., Verdejo-Garcia A. Brain structural correlates of reward sensitivity and impulsivity in adolescents with normal and excess weight. PLoS ONE 2012, 7:e49185.
254. Morgan C., Colombres M., Nunez M.T., Inestrosa N.C. Structure and function of amyloid in Alzheimer's disease. Prog. Neurobiol. 2004, 74:323-349.
255. Muhlhausler B.S., Adam C.L., McMillen I.C. Maternal nutrition and the programming of obesity: the brain. Organogenesis 2008, 4:144-152.
256. Mulder M., Ravid R., Swaab D.F., de Kloet E.R., Haasdijk E.D., Julk J., van der Boom J.J., Havekes L.M. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 1998, 12:198-203.
257. Murray I.V., Proza J.F., Sohrabji F., Lawler J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. (Maywood) 2011, 236:772-782.
258. Newton J.L. Systemic symptoms in non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:214-219.
259. Nickey W.A., Lenfant C., Chobanian A.V., Roccella E.J. The National High Blood Pressure Education Program: longtime partners with new strategies. J. Am. Osteopath. Assoc. 2003, 103:297-299.
260. Niculescu M.D., Lupu D.S. High fat diet-induced maternal obesity alters fetal hippocampal development. Int. J. Dev. Neurosci.: Off. J. Int. Soc. Dev. Neurosci. 2009, 27:627-633.
261. Nicholson D.W. Neuroscience: good and bad cell death. Nature 2009, 457:970-971.
262. Niehrs C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 2012, 13:767-779.
263. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
264. Nishi M., Steiner D.F. Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a New World rodent, the degu, Octodon degus. Mol. Endocrinol. 1990, 4:1192-1198.
265. Nusse R. Wnt signaling. Cold Spring Harb. Perspect. Biol. 2012, 4:1-3.
266. Nusse R., Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012, 31:2670-2684.
267. O'Malley D., MacDonald N., Mizielinska S., Connolly C.N., Irving A.J., Harvey J. Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol. Cell. Neurosci. 2007, 35:559-572.
268. O'Reilly J.R., Reynolds R.M. The risk of maternal obesity to the long-term health of the offspring. Clin. Endocrinol. (Oxf.) 2013, 78:9-16.
269. Oh K.J., Park J., Kim S.S., Oh H., Choi C.S., Koo S.H. TCF7L2 modulates glucose homeostasis by regulating CREB- and FoxO1-dependent transcriptional pathway in the liver. PLoS Genet. 2012, 8:e1002986.
270. Ohshima K., Mogi M., Horiuchi M. Therapeutic approach for neuronal disease by regulating renin-angiotensin system. Curr. Hypertens. Rev. 2013, 9:99-107.
271. Oliva C.A., Vargas J.Y., Inestrosa N.C. Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front. Cell. Neurosci. 2013, 7:224.
272. Opazo J.C., Soto-Gamboa M., Bozinovic F. Blood glucose concentration in caviomorph rodents. Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 2004, 137:57-64.
273. Palsgaard J., Emanuelli B., Winnay J.N., Sumara G., Karsenty G., Kahn C.R. Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J. Biol. Chem. 2012, 287:12016-12026.
274. Panza F., D'Introno A., Colacicco A.M., Capurso C., Pichichero G., Capurso S.A., Capurso A., Solfrizzi V. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 2006, 51:275-292.
275. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 2003, 60:29-35.
276. Parish C.L., Castelo-Branco G., Rawal N., Tonnesen J., Sorensen A.T., Salto C., Kokaia M., Lindvall O., Arenas E. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Investig. 2008, 118:149-160.
277. Parish C.L., Thompson L.H. Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease. J. Mol. Cell Biol. 2014, 6:54-63.
278. Park C.R., Seeley R.J., Craft S., Woods S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 2000, 68:509-514.
279. Parr C., Carzaniga R., Gentleman S.M., Van Leuven F., Walter J., Sastre M. Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol. Cell. Biol. 2012, 32:4410-4418.
280. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 1997, 56:70-78.
281. Piaceri I., Nacmias B., Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front. Biosci. (Elite Ed.) 2013, 5:167-177.
282. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 2000, 924:81-90.
283. Porte D., Baskin D.G., Schwartz M.W. Leptin and insulin action in the central nervous system. Nutr. Rev. 2002, 60:S20-S29. (discussion S68-S84, 85-87).
284. Porte D., Baskin D.G., Schwartz M.W. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54:1264-1276.
285. Power M.L., Schulkin J. Maternal obesity, metabolic disease, and allostatic load. Physiol. Behav. 2012, 106:22-28.
286. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Jolles J., Koudstaal P.J., Hofman A., Breteler M.M. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005, 128:2034-2041.
287. Pulkkinen K., Murugan S., Vainio S. Wnt signaling in kidney development and disease. Organogenesis 2008, 4:55-59.
288. Purro S.A., Dickins E.M., Salinas P.C. The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J. Neurosci.: Off. J. Soc. Neurosci. 2012, 32:3492-3498.
289. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
290. Rabbani N., Thornalley P.J. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann. N. Y. Acad. Sci. 2008, 1126:124-127.
291. Rask-Andersen M., Jacobsson J.A., Moschonis G., Ek A.E., Chrousos G.P., Marcus C., Manios Y., Fredriksson R., Schioth H.B. The MAP2K5-linked SNP rs2241423 is associated with BMI and obesity in two cohorts of Swedish and Greek children. BMC Med. Genet. 2012, 13:36.
292. Razay G., Vreugdenhil A., Wilcock G. The metabolic syndrome and Alzheimer disease. Arch. Neurol. 2007, 64:93-96.
293. Reinert K.R., Po'e E.K., Barkin S.L. The relationship between executive function and obesity in children and adolescents: a systematic literature review. J. Obes. 2013, 2013:820956.
294. Reitz C., Tang M.X., Schupf N., Manly J.J., Mayeux R., Luchsinger J.A. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol. 2010, 67:1491-1497.
295. Ribeiro-Oliveira A., Nogueira A.I., Pereira R.M., Boas W.W., Dos Santos R.A., Simoes e Silva A.C. The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 2008, 4:787-803.
296. Roberts R.O., Knopman D.S., Geda Y.E., Cha R.H., Pankratz V.S., Baertlein L., Boeve B.F., Tangalos E.G., Ivnik R.J., Mielke M.M., Petersen R.C. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimer's Dement.: J. Alzheimer's Assoc. 2014, 10:18-26.
297. Robin N.C., Agoston Z., Biechele T.L., James R.G., Berndt J.D., Moon R.T. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Stem Cell Rep. 2014, 2:9-17.
298. Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.M., Kalback W., Anthony J., Watson D., Luehrs D.C., Sue L., Walker D., Emmerling M., Goux W., Beach T. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002, 41:11080-11090.
299. Rooney B., O'Donovan H., Gaffney A., Browne M., Faherty N., Curran S.P., Sadlier D., Godson C., Brazil D.P., Crean J. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 2011, 585:531-538.
300. Rosenstiel P., Gallinat S., Arlt A., Unger T., Sievers J., Lucius R. Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?. CNS Drugs 2002, 16:145-153.
301. Roses A.D. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J. Alzheimers Dis. 2006, 9:361-366.
302. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., MacDougald O.A. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
303. Rosso S.B., Inestrosa N.C. WNT signaling in neuronal maturation and synaptogenesis. Front. Cell. Neurosci. 2013, 7:103.
304. Roth C.L., Elfers C., Gebhardt U., Muller H.L., Reinehr T. Brain-derived neurotrophic factor and its relation to leptin in obese children before and after weight loss. Metabolism 2013, 62:226-234.
305. Rushworth J.V., Hooper N.M. Lipid rafts: linking Alzheimer's amyloid-beta production, aggregation, and toxicity at neuronal membranes. Int. J. Alzheimers Dis. 2010, 2011:603052.
306. Saadi-Kheddouci S., Berrebi D., Romagnolo B., Cluzeaud F., Peuchmaur M., Kahn A., Vandewalle A., Perret C. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001, 20:5972-5981.
307. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D., et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils, Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 1994, 94:860-869.
308. Sanz C., Andrieu S., Sinclair A., Hanaire H., Vellas B., Group R.F.S. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009, 73:1359-1366.
309. Sato N., Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front. Aging Neurosci. 2013, 5:64.
310. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr. Mol. Med. 2006, 6:351-358.
311. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Dement. 2006, 21:197-208.
312. Savaskan E., Hock C., Olivieri G., Bruttel S., Rosenberg C., Hulette C., Muller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol. Aging 2001, 22:541-546.
313. Schelp A.O., Mendes-Chiloff C.L., Bazan R., Paduan V.C., Pioltini A.B. Metabolic syndrome and dementia associated with Parkinson's disease: impact of age and hypertension. Arq. Neuropsiquiatr. 2012, 70:114-118.
314. Schioth H.B., Craft S., Brooks S.J., Frey W.H., Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol. 2013, 46:4-10.
315. Schwartz M.W., Baskin D.G. Leptin and the brain: then and now. J. Clin. Invest. 2013, 123:2344-2345.
316. Selkoe D., Mandelkow E., Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a011460.
317. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol. Clin. 2000, 18:903-922.
318. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1:a006189.
319. Seto S., Yumoto K., Okada K., Asahina Y., Iwane A., Iwago M., Terasawa R., Shreder K.R., Murakami K., Kohno Y. Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3beta (GSK-3beta) inhibitors for type 2 diabetics. Bioorg. Med. Chem. 2012, 20:1188-1200.
320. Sharma S., Zhuang Y., Gomez-Pinilla F. High-fat diet transition reduces brain DHA levels associated with altered brain plasticity and behaviour. Sci. Rep. 2012, 2:431.
321. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 2011, 68:1239-1244.
322. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 2011, 68:1385-1392.
323. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.F., Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., Da Silva H.A., Haines J.L., Perkicak-Vance M.A., Tanzi R.E., Roses A.D., Fraser P.E., Rommens J.M., St George-Hyslop P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
324. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 2001, 22:397-402.
325. Silva-Alvarez C., Arrazola M.S., Godoy J.A., Ordenes D., Inestrosa N.C. Canonical Wnt signaling protects hippocampal neurons from Abeta oligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. Front. Cell. Neurosci. 2013, 7:97.
326. Simons M., Mlodzik M. Planar cell polarity signaling: from fly development to human disease. Annu. Rev. Genet. 2008, 42:517-540.
327. Singh R., Smith E., Fathzadeh M., Liu W., Go G.W., Subrahmanyan L., Faramarzi S., McKenna W., Mani A. Rare nonconservative LRP6 mutations are associated with metabolic syndrome. Hum. Mutat. 2013, 34:1221-1225.
328. Skledar M., Nikolac M., Dodig-Curkovic K., Curkovic M., Borovecki F., Pivac N. Association between brain-derived neurotrophic factor Val66Met and obesity in children and adolescents. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2012, 36:136-140.
329. Skoog I., Gustafson D. Update on hypertension and Alzheimer's disease. Neurol. Res. 2006, 28:605-611.
330. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9866-9868.
331. Solfrizzi V., Scafato E., Capurso C., D'Introno A., Colacicco A.M., Frisardi V., Vendemiale G., Baldereschi M., Crepaldi G., Di Carlo A., Galluzzo L., Gandin C., Inzitari D., Maggi S., Capurso A., Panza F., Italian Longitudinal Study on Ageing Working Group Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J. Neurol. Neurosurg. Psychiatry 2010, 81:433-440.
332. Song F., Schmidt A.M. Glycation and insulin resistance: novel mechanisms and unique targets?. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1760-1765.
333. Sparks D.L., Ziolkowski C., Lawmaster T., Martin T. Influence of water quality on cholesterol-induced tau pathology: preliminary data. Int. J. Alzheimer's Dis. 2011, 2011:987023.
334. Stachowiak E.K., Oommen S., Vasu V.T., Srinivasan M., Stachowiak M., Gohil K., Patel M.S. Maternal obesity affects gene expression and cellular development in fetal brains. Nutr. Neurosci. 2013, 16:96-103.
335. Stachowiak E.K., Srinivasan M., Stachowiak M.K., Patel M.S. Maternal obesity induced by a high fat diet causes altered cellular development in fetal brains suggestive of a predisposition of offspring to neurological disorders in later life. Metab. Brain Dis. 2013, 28:721-725.
336. Steculorum S.M., Solas M., Bruning J.C. The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimer's Dement.: J. Alzheimer's Assoc. 2014, 10:S3-S11.
337. Stranahan A.M., Arumugam T.V., Cutler R.G., Lee K., Egan J.M., Mattson M.P. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11:309-317.
338. Stranahan A.M., Norman E.D., Lee K., Cutler R.G., Telljohann R.S., Egan J.M., Mattson M.P. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008, 18:1085-1088.
339. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
340. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8098-8102.
341. Supnet C., Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S487-S498.
342. Surendran K., Schiavi S., Hruska K.A. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J. Am. Soc. Nephrol. 2005, 16:2373-2384.
343. Sutinen E.M., Pirttila T., Anderson G., Salminen A., Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J. Neuroinflammation 2012, 9:199.
344. Takeda S., Sato N., Rakugi H., Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol. Biosyst. 2011, 7:1822-1827.
345. Tamboli I.Y., Barth E., Christian L., Siepmann M., Kumar S., Singh S., Tolksdorf K., Heneka M.T., Lutjohann D., Wunderlich P., Walter J. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J. Biol. Chem. 2010, 285:37405-37414.
346. Tan B., Choi R.H., Chin T.J., Kaur C., Ling E.A. Manipulation of microglial activity as a therapy for Alzheimer's disease. Front. Biosci. (Schol Ed.) 2012, 4:1402-1412.
347. Tandon A., Rogaeva E., Mullan M., St George-Hyslop P.H. Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr. Opin. Neurol. 2000, 13:377-384.
348. Tao G.Z., Lehwald N., Jang K.Y., Baek J., Xu B., Omary M.B., Sylvester K.G. Wnt/beta-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J. Biol. Chem. 2013, 288:17214-17224.
349. Tarantino G., Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. World J. Gastroenterol. 2013, 19:3375-3384.
350. Tarragon E., Lopez D., Estrada C., Ana G.C., Schenker E., Pifferi F., Bordet R., Richardson J.C., Herrero M.T. Octodon degus: A model for the cognitive impairment associated with Alzheimer's disease. CNS Neurosci. Ther. 2013, 9(9):643-648. 10.1111/cns.12125.
351. Tennant K.A., Brown C.E. Diabetes augments in vivo microvascular blood flow dynamics after stroke. J. Neurosci.: Off. J. Soc. Neurosci. 2013, 33:19194-19204.
352. Thal D.R., Glas A., Schneider W., Schober R. Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Acta Neuropathol. 1997, 94:255-265.
353. Thompson M.D., Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
354. Tirsi A., Duong M., Tsui W., Lee C., Convit A. Retinal vessel abnormalities as a possible biomarker of brain volume loss in obese adolescents. Obesity 2013, 12:E577-E585. 10.1002/oby.20450.
355. Tokutake T., Kasuga K., Yajima R., Sekine Y., Tezuka T., Nishizawa M., Ikeuchi T. Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J. Biol. Chem. 2012, 287:35222-35233.
356. Toledo E.M., Inestrosa N.C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry 2010, 15:272-285. 228.
357. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
358. Umegaki H. Neurodegeneration in diabetes mellitus. Adv. Exp. Med. Biol. 2012, 724:258-265.
359. Valerio A., Ghisi V., Dossena M., Tonello C., Giordano A., Frontini A., Ferrario M., Pizzi M., Spano P., Carruba M.O., Nisoli E. Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. J. Biol. Chem. 2006, 281:12950-12958.
360. van de Schans V.A., van den Borne S.W., Strzelecka A.E., Janssen B.J., van der Velden J.L., Langen R.C., Wynshaw-Boris A., Smits J.F., Blankesteijn W.M. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 2007, 49:473-480.
361. Van Gassen G., Annaert W. Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 2003, 9:117-126.
362. van Groen T., Kadish I., Popovic N., Popovic M., Caballero-Bleda M., Bano-Otalora B., Vivanco P., Rol M.A., Madrid J.A. Age-related brain pathology in Octodon degu: blood vessel, white matter and Alzheimer-like pathology. Neurobiol. Aging 2011, 32:1651-1661.
363. Vance J.E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Models Mech. 2012, 5:746-755.
364. Vanhanen M., Koivisto K., Moilanen L., Helkala E.L., Hanninen T., Soininen H., Kervinen K., Kesaniemi Y.A., Laakso M., Kuusisto J. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006, 67:843-847.
365. Varela-Nallar L., Alfaro I.E., Serrano F.G., Parodi J., Inestrosa N.C. Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21164-21169.
366. Vargas J.Y., Fuenzalida M., Inestrosa N.C. In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer's disease model. J. Neurosci.: Off. J. Soc. Neurosci. 2014, 34:2191-2202.
367. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 2000, 20:1657-1665.
368. Vemuri P., Lesnick T.G., Przybelski S.A., Knopman D.S., Roberts R.O., Lowe V.J., Kantarci K., Senjem M.L., Gunter J.L., Boeve B.F., Petersen R.C., Jack C.R. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann. Neurol. 2012, 72:730-738.
369. Vignini A., Giulietti A., Nanetti L., Raffaelli F., Giusti L., Mazzanti L., Provinciali L. Alzheimer's disease and diabetes: new insights and unifying therapies. Curr. Diabetes Rev. 2013, 9:218-227.
370. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis. 2010, 9:144.
371. Von Bernhardi R., Zanlungo S., Arrese M., Arteaga A., Rigotti A. The metabolic syndrome: from an aggravating condition to a pathogenic risk factor for chronic diseases. Rev. Med. Chile 2010, 138:1012-1019.
372. Wang H.Y., Liu T., Malbon C.C. Structure-function analysis of Frizzleds. Cell. Signal. 2006, 18:934-941.
373. Wang J., Bi W., Cheng A., Freire D., Vempati P., Zhao W., Gong B., Janle E., Chen T.-Y., Ferruzzi M., Schmeidler J., Ho L., Pasinetti G.M. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease: experimental approach and therapeutic implications. Front. Aging Neurosci. 2014, 6:1-10.
374. Wang J., Ho L., Qin W., Rocher A.B., Seror I., Humala N., Maniar K., Dolios G., Wang R., Hof P.R., Pasinetti G.M. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2005, 19:659-661.
375. Wang Q., Usinger W., Nichols B., Gray J., Xu L., Seeley T.W., Brenner M., Guo G., Zhang W., Oliver N., Lin A., Yeowell D. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenes. Tissue Repair 2011, 4:4.
376. Wang X., Lei X.G., Wang J. Malondialdehyde regulates glucose-stimulated insulin secretion in murine islets via TCF7L2-dependent Wnt signaling pathway. Mol. Cell. Endocrinol. 2014, 382:8-16.
377. Ward A., Crean S., Mercaldi C.J., Collins J.M., Boyd D., Cook M.N., Arrighi H.M. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 2012, 38:1-17.
378. Watts A.S., Loskutova N., Burns J.M., Johnson D.K. Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults. J. Alzheimer's Dis. 2013, 35:253-265.
379. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., Allen K., Lopes M., Savoye M., Morrison J., Sherwin R.S., Caprio S. Obesity and the metabolic syndrome in children and adolescents. New Engl. J. Med. 2004, 350:2362-2374.
380. Whitmer R.A., Gunderson E.P., Quesenberry C.P., Zhou J., Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 2007, 4:103-109.
381. Wiesmann M., Kiliaan A.J., Claassen J.A. Vascular aspects of cognitive impairment and dementia. J. Cereb. Blood Flow Metab.: Off. J. Int. Soc. Cereb. Blood Flow Metab. 2013, 33:1696-1706.
382. Wilson C. Diabetes: human beta-cell proliferation by promoting Wnt signalling. Nat. Rev. Endocrinol. 2013, 9:502.
383. Wimo A., Jonsson L., Bond J., Prince M., Winblad B., Alzheimer Disease International The worldwide economic impact of dementia 2010. Alzheimer's Dement.: J. Alzheimer's Assoc. 2013, 9:1-11. e13.
384. Wozniak M., Rydzewski B., Baker S.P., Raizada M.K. The cellular and physiological actions of insulin in the central nervous system. Neurochem. Int. 1993, 22:1-10.
385. Wright W.S., Longo K.A., Dolinsky V.W., Gerin I., Kang S., Bennett C.N., Chiang S.H., Prestwich T.C., Gress C., Burant C.F., Susulic V.S., MacDougald O.A. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes 2007, 56:295-303.
386. Wu T., Deng S., Li W.G., Yu Y., Li F., Mao M. Maternal obesity caused by overnutrition exposure leads to reversal learning deficits and striatal disturbance in rats. PLOS ONE 2013, 8:e78876.
387. Wu W., Brickman A.M., Luchsinger J., Ferrazzano P., Pichiule P., Yoshita M., Brown T., DeCarli C., Barnes C.A., Mayeux R., Vannucci S.J., Small S.A. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann. Neurol. 2008, 64:698-706.
388. Wuebken A., Schmidt-Ott K.M. WNT/beta-catenin signaling in polycystic kidney disease. Kidney Int. 2011, 80:135-138.
389. Xu W.L., Atti A.R., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
390. Xu Y., Gong W., Peng J., Wang H., Huang J., Ding H., Wang D.W. Functional analysis LRP6 novel mutations in patients with coronary artery disease. PLOS ONE 2014, 9:e84345.
391. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., Smith M.A., et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:7787-7791.
392. Yang H., Li Q., Lee J.H., Shu Y. Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice. Int. J. Biol. Sci. 2012, 8:791-801.
393. Yang Y., Zhang J., Ma D., Zhang M., Hu S., Shao S., Gong C.X. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimer's Dis. 2013, 37:637-648.
394. Yates K.F., Sweat V., Yau P.L., Turchiano M.M., Convit A. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2060-2067.
395. Yau P.L., Castro M.G., Tagani A., Tsui W.H., Convit A. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics 2012, 130:e856-e864.
396. Yau P.L., Javier D.C., Ryan C.M., Tsui W.H., Ardekani B.A., Ten S., Convit A. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 2010, 53:2298-2306.
397. Yoon J.C., Ng A., Kim B.H., Bianco A., Xavier R.J., Elledge S.J. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev. 2010, 24:1507-1518.
398. Zeggini E., McCarthy M.I. TCF7L2: the biggest story in diabetes genetics since HLA?. Diabetologia 2007, 50:1-4.
399. Zhang X., Li L., Zhang X., Xie W., Li L., Yang D., Heng X., Du Y., Doody R.S., Le W. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol. Aging 2013, 34:663-678.
400. Zhang Y.Y., Fan Y.C., Wang M., Wang D., Li X.H. Atorvastatin attenuates the production of IL-1beta, IL-6, and TNF-alpha in the hippocampus of an amyloid beta1-42-induced rat model of Alzheimer's disease. Clin. Interv. Aging 2013, 8:103-110.
401. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., Clevers H., Saftig P., De Strooper B., He X., Yankner B.A. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998, 395:698-702.
402. Zhou D., Strakovsky R.S., Zhang X., Pan Y.X. The skeletal muscle Wnt pathway may modulate insulin resistance and muscle development in a diet-induced obese rat model. Obesity 2012, 20:1577-1584.
403. Zilberberg A., Yaniv A., Gazit A. The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the canonical Wnt signaling pathway. J. Biol. Chem. 2004, 279:17535-17542.
404. Zimmerman Z.F., Moon R.T., Chien A.J. Targeting Wnt pathways in disease. Cold Spring Harb. Perspect. Biol. 2012, 4(11).
405. Zlokovic B.V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. J. Am. Med. Assoc. Neurol. 2013, 70:440-444.
406. Zolezzi J.M., Inestrosa N.C. Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier. Mol. Neurobiol. 2013, 48(3):438-451. 10.1007/s12035-013-8435-5.
407. Zolezzi J.M., Inestrosa N.C. Brain metabolite clearance: impact on Alzheimer's disease. Metab. Brain Dis. 2014, (Epub ahead of print).
408. Zolezzi J.M., Silva-Alvarez C., Ordenes D., Godoy J.A., Carvajal F.J., Santos M.J., Inestrosa N.C. Peroxisome proliferator-activated receptor (PPAR) gamma and PPARalpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?. PLOS ONE 2013, 8:e64019.